Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.

Journal Article (Journal Article)

The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B*58:01 Genotype and Allopurinol Dosing was originally published in February 2013. We reviewed the recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplemental Material and included additional resources for applying CPIC guidelines into the electronic health record. Up-to-date information can be found at PharmGKB (

Full Text

Duke Authors

Cited Authors

  • Saito, Y; Stamp, LK; Caudle, KE; Hershfield, MS; McDonagh, EM; Callaghan, JT; Tassaneeyakul, W; Mushiroda, T; Kamatani, N; Goldspiel, BR; Phillips, EJ; Klein, TE; Lee, MTM; Clinical Pharmacogenetics Implementation Consortium,

Published Date

  • January 2016

Published In

Volume / Issue

  • 99 / 1

Start / End Page

  • 36 - 37

PubMed ID

  • 26094938

Pubmed Central ID

  • PMC4675696

Electronic International Standard Serial Number (EISSN)

  • 1532-6535

Digital Object Identifier (DOI)

  • 10.1002/cpt.161


  • eng

Conference Location

  • United States